MUMBAI, Nov. 26, 2015 /CNW/ - Accutest Research Laboratories, a leading independent and internationally accredited Contract Research Organization (CRO), has formed a strategic partnership with Fox Chase Cancer Center - Temple Health for joint work on clinical trials.
The partnership aims to offer a strategic research platform for Fox Chase Cancer Center - Temple Health and Accutest Research Laboratories to conduct clinical trials in the United States, India, Southeast Asia and Latin America.
"This partnership will enable Fox Chase Cancer Center, a nationally ranked, NCI-designated comprehensive cancer center, to offer its expertise to the Asian market, expand its research and development initiatives and leverage emerging markets to the benefit of larger patient populations," said Dr. Kurt Schwinghammer, vice president for research and development alliances at Fox Chase Cancer Center - Temple Health.
Representatives of both organizations signed a non-binding memorandum of understanding on November 10, 2015, in New Delhi, India.
"Becoming a contract research organization partner with Fox Chase Cancer Center - Temple Health will allow Accutest Research Laboratories to further leverage our scientific competence, timely delivery and other capabilities to execute Phase II to IV clinical trials in emerging countries," said Dr. Satish Sawant, chief executive officer and founder of Accutest Research Laboratories.
About Fox Chase Cancer Center
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
About Accutest Research Laboratory
Accutest Research Laboratory is a leading global independent and internationally accredited CRO, offering services to customers around the world. Since its inception in 1998, the company has built an unmatched platform to provide end-to-end services to pharmaceutical and biotechnology companies globally. Accutest is the market leader amongst independent CROs, with the highest quality standards, quick turnaround time and a strong regulatory track record of 80+ accreditations/ approvals from global regulatory agencies like USFDA, WHO, ANVISA, EMA, DCGI, MCC, MOH-Turkey, NPCB-Malaysia and many more. Its services include Phase I Bioavailability/Bioequivalence (BA/BE) Studies, Phase II - IV Clinical Development Services (CDS) and Biosimilars Services. Accutest has capabilities to execute Phase II to IV clinical trials in Asia and Latin America. It offers end-to-end services for small molecules, big molecules and medical devices under CDS roof, which covers Clinical Operations, Clinical Data Management, Pharmacovigilance, and Medical Writing services. These services are offered as a standalone or as a bundled package. Their mission is 'to become the preferred CRO partner to pharmaceutical and biotechnology companies globally, by means of scientific competence, timely delivery, cost effectiveness and recognition.'
SOURCE Accutest Research Laboratories (I) Pvt. Ltd.